ESC 365 - Phospholamban antisense therapy reduces phospholamban aggregation and enhances calcium and contractile kinetics in human phospholamban cardiomyopathy

Open Access

Phospholamban antisense therapy reduces phospholamban aggregation and enhances calcium and contractile kinetics in human phospholamban cardiomyopathy

Session: Young Investigator Award (YIA) Basic Science

Topic: Gene Therapy, Cell Therapy

Speaker: Mr F. Deiman (Groningen, NL)

Event: Heart Failure 2025

Congress Presentation

Add to my library

About the speaker

Mr Frederik Ernst Deiman

University Medical Centre Groningen, Groningen (Netherlands (The))

0 follower

3 more presentations in this session

Dapagliflozin in primary prevention of cardiotoxicity induced by anthracycline-trastuzumab therapy through activation of pAMPK and inhibition of MyD88 and NLRP-3

Speaker: Doctor V. Quagliariello (Naples, IT)

Engineering genetic resilience for cardiometabolic HFpEF: the crucial role of redox homeostasis

Speaker: Doctor M. Pepin (Stanford, US)

A multifactorial porcine model of cardio-metabolic HFpEF highlights miR-483-3p as a promising target therapy

Speaker: Miss K. Kohlat (German Heart Center Of Charite Berlin, DE)

Access the full session

Young Investigator Award (YIA) Basic Science

Speakers: Mr F. Deiman, Doctor V. Quagliariello, Doctor M. Pepin, Miss K. Kohlat

About the event

Heart Failure 2025

17 May - 20 May 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources

Explore sponsored resources